清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

医学 肿瘤科 化疗 食管鳞状细胞癌 内科学 基底细胞 随机对照试验 新辅助治疗 癌症 乳腺癌
作者
Jianjun Qin,Liyan Xue,Anlin Hao,Xiaofeng Guo,Tao Jiang,Yunfeng Ni,Shuoyan Liu,Yujie Chen,Hongjing Jiang,Chen Zhang,Mingqiang Kang,Jihong Lin,Hecheng Li,Chengqiang Li,Hui Tian,Lin Li,Junke Fu,Yong Zhang,Jianqun Ma,Xiaoyuan Wang,Maoyong Fu,Hao Yang,Zhaoyang Yang,Yongtao Han,Long-Qi Chen,Lijie Tan,Tianyang Dai,Yongde Liao,Weiguo Zhang,Bin Li,Qixun Chen,Guo Shiping,Yu Qi,Li Wei,Zhigang Li,Ziqiang Tian,Xiaozheng Kang,Ruixiang Zhang,Yong Li,Zhen Wang,Xiankai Chen,Zhiguo Hou,Rongrong Zheng,Wenqing Zhu,Jie He,Yin Li
出处
期刊:Nature Medicine [Springer Nature]
卷期号:30 (9): 2549-2557 被引量:5
标识
DOI:10.1038/s41591-024-03064-w
摘要

Recent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have shown promising results. This multicenter, randomized, open-label phase 3 trial aimed to further assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy followed by adjuvant camrelizumab, compared to neoadjuvant chemotherapy alone. A total of 391 patients with resectable thoracic LA-ESCC (T1b-3N1-3M0 or T3N0M0) were stratified by clinical stage (I/II, III or IVA) and randomized in a 1:1:1 ratio to undergo two cycles of neoadjuvant therapy. Treatments included camrelizumab, albumin-bound paclitaxel and cisplatin (Cam+nab-TP group; n = 132); camrelizumab, paclitaxel and cisplatin (Cam+TP group; n = 130); and paclitaxel with cisplatin (TP group; n = 129), followed by surgical resection. Both the Cam+nab-TP and Cam+TP groups also received adjuvant camrelizumab. The dual primary endpoints were the rate of pathological complete response (pCR), as evaluated by a blind independent review committee, and event-free survival (EFS), as assessed by investigators. This study reports the final analysis of pCR rates. In the intention-to-treat population, the Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group (Cam+nab-TP versus TP: difference 23.5%, 95% confidence interval (CI) 15.1-32.0, P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7-18.1, P = 0.0034). The study met its primary endpoint of pCR; however, EFS is not yet mature. The incidence of grade ≥3 treatment-related adverse events during neoadjuvant treatment was 34.1% for the Cam+nab-TP group, 29.2% for the Cam+TP group and 28.8% for the TP group; the postoperative complication rates were 34.2%, 38.8% and 32.0%, respectively. Neoadjuvant camrelizumab plus chemotherapy demonstrated superior pCR rates compared to chemotherapy alone for LA-ESCC, with a tolerable safety profile. Chinese Clinical Trial Registry identifier: ChiCTR2000040034 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
aaliyah完成签到 ,获得积分10
16秒前
1分钟前
1437594843完成签到 ,获得积分10
1分钟前
bkagyin应助宋丽薇采纳,获得20
2分钟前
3分钟前
机智若云完成签到,获得积分10
3分钟前
3分钟前
宋丽薇发布了新的文献求助20
3分钟前
4分钟前
宋丽薇完成签到,获得积分10
4分钟前
日暮炊烟完成签到 ,获得积分10
4分钟前
4分钟前
SciGPT应助笑点低涵雁采纳,获得10
4分钟前
iShine完成签到 ,获得积分10
5分钟前
5分钟前
5分钟前
mellow完成签到,获得积分10
5分钟前
爱心完成签到 ,获得积分10
5分钟前
笑点低涵雁完成签到,获得积分20
5分钟前
6分钟前
稻子完成签到 ,获得积分10
6分钟前
7分钟前
今后应助able采纳,获得10
7分钟前
7分钟前
able发布了新的文献求助10
7分钟前
juan完成签到 ,获得积分10
8分钟前
自然的含蕾完成签到 ,获得积分10
9分钟前
蛋蛋发布了新的文献求助10
9分钟前
碗碗豆喵完成签到 ,获得积分10
9分钟前
沙海沉戈完成签到,获得积分0
9分钟前
蛋蛋完成签到 ,获得积分20
9分钟前
万能图书馆应助Magali采纳,获得10
10分钟前
11分钟前
CipherSage应助科研通管家采纳,获得10
12分钟前
12分钟前
Tttttttt完成签到,获得积分10
12分钟前
石头完成签到,获得积分10
13分钟前
13分钟前
咯咯咯完成签到 ,获得积分10
13分钟前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3081580
求助须知:如何正确求助?哪些是违规求助? 2734437
关于积分的说明 7532802
捐赠科研通 2383917
什么是DOI,文献DOI怎么找? 1264100
科研通“疑难数据库(出版商)”最低求助积分说明 612563
版权声明 597578